Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.
Matterhorn Biosciences is a biotechnology company focusing on the discovery of cellular therapies targeting the MR1 molecule.
Oyster is a clinical stage pharmaceutical company focused on the discovery development & commercialization .
Sebacia is a commercial-stage dermatology company that develops an alternative to the topical and systemic drugs for the treatment of acne.
Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases.
Gotham Therapeutics is discovering a novel drug class targeting the epitranscriptomics machinery.
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases
Inari Medical is a medical device company that develops devices for the interventional treatment of cardiovascular diseases.
Metavention develops medical devices to help with interventional therapies for high blood pressure and other metabolic diseases.
Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis.
It is a regenerative medicine company.
ForSight VISION5 was founded in 2010 as the fifth company created by the ophthalmic product incubator, ForSight Labs.
Inception IBD is focused on translating academic discoveries in the field of IBD
Cotera develops orthopedic devices such as implantable devices for the treatment of knee osteoarthritis.
Inception Sciences creates therapies with transformative potential to address diseases and disorders with significant unmet need.
Versant Ventures has invested in 89 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Versant Ventures's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Medical Device. The firm invests across 13 different industry categories.
Among tracked funding rounds, BlueRock Therapeutics received $225.0M in a Series A round. Versant Ventures's total known invested capital is $4.4B.
Versant Ventures's average investment size is $68.2M across its portfolio of 89 companies.
Recent Versant Ventures portfolio additions include Vividion Therapeutics, Passage Bio, Lava Therapeutics, Matterhorn Biosciences, Oyster Point Pharmaceuticals. These companies were founded in 2020 or later.